The current study for the first time demonstrated the worse and time dependent prognostic impact of TOP2A overexpression in early stage luminal breast cancer patients, suggesting the potential value of TOP2A as a predictor of late recurrence for this subtype of breast cancer. This evidence concerns the gene TOP2A and breast carcinoma.